Functionalized graphene oxide as a nanocarrier for delivering oridonin to improve anti‐breast cancer cell activity

• Published in: Biomedical chromatography 2024-08, Vol.38 (8), p.e5943-n/a
• Main Authors: Zhang, Xin‐yan, Shi, Xiao‐zi, Yu, Jia‐yuan, Wang, Jin, Zhao, Yong‐ming
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Breast Neoplasms - drug therapy; Cell Survival - drug effects; Chromatography, High Pressure Liquid - methods; Diterpenes, Kaurane - chemistry; Diterpenes, Kaurane - pharmacology; Drug Carriers - chemistry; drug delivery systems; Drug Liberation; Female; Folic Acid - chemistry; graphene oxide; Graphite - chemistry; Humans; MCF-7 Cells; Nanoparticles - chemistry; nanotechnology; ultra‐high‐performance liquid chromatography
• ISSN: 0269-3879; 1099-0801; 1099-0801
• DOI: 10.1002/bmc.5943

In this study, a targeted nanocarrier was developed by functionalizing graphene oxide with polyethyleneimine and folic acid, intended for loading oridonin. The nanocarrier was successfully synthesized and characterized using an ultraviolet spectrum, Fourier transform infrared spectroscopy and scanning electron microscopy. The nanocarrier demonstrated a remarkable oridonin loading capacity, reaching 424.8 μg/mg, as determined by ultra‐high performance liquid chromatography. In vitro drug release experiments exhibited a pH‐dependent release profile, with a higher cumulative release in an acidic environment. The release mechanism followed the Ritger–Peppas equation model. Cytotoxicity assays indicated minimal toxicity of the nanocarrier. Enhanced cellular uptake by MCF7 cells was observed for carriers functionalized with folate and polyethyleneimine. These findings highlight the potential of functionalized graphene oxide as a promising carrier for oridonin delivery in biomedical applications.